Diretriz preliminar da USPSTF revisa a diretriz anterior e agora recomenda contra iniciar aspirina em baixa dose como prevenção primária de doença cardiovascular (DCV) em pessoas com 60 anos de idade ou mais.

USPSTF Draft Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease – U.S. Preventive Services Task Force

Comentários:

Advice shifting on aspirin use for preventing heart attacks – Associated Press

Taking aspirin to prevent heart attack may cause more harm than good, task force says – NPR

Estudos randomizados relacionados:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Metanálises relacionadas:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Opiniões relacionadas:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist

Comentário no Twitter

Low Dose Aspirin in the Primary Prevention of Cardiovascular Disease: #USPSTF recommends individualized decision making between 50 and 59 years, and against aspirin use in 60 years+. What a difference a few years can make, with more data and evidence. https://t.co/3nC3jpjTDq pic.twitter.com/SN8K3Z9XJj

— Muin J. Khoury (@MuinJKhoury) October 12, 2021